|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
fatigue |
|
headache |
|
insomnia |
|
Bronchitis |
|
Diarrhea |
|
nausea |
|
vomiting |
|
Abdominal pain |
|
conjunctivitis |
|
cough |
|
dizziness |
|
ear disorder |
|
epistaxis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
|
|
ADULT DOSE:
|
|
Influenza A (treatment) or
Influenza B (treatment)-
Oral, 75 milligrams (mg) two times a day for 5 days. Oseltamivir should be initiated within 2 days of influenza symptoms.
Note: Renal Impairment: In patients with a creatinine clearance of less than 30 mL/min the recommended dose is 75 mg once daily for 5 days. Use of oseltamivir in patients with renal failure (creatinine clearance below 10 mL/min) has not been studied .
No recommended dose regimens are available for patients having routine hemodialysis and continuous peritoneal dialysis treatment with end-stage renal disease.
Influenza (prophylaxis) -
Oral, 75 mg once a day for at least 7 days. Oseltamivir should be initiated within 2 days of influenza exposure.
Note: Renal Impairment: In patients with a creatinine clearance between 10 and 30 mL/min, the recommended dose is 75 mg once every other day. No recommended dose regimens are available for patients having routine hemodialysis and continuous peritoneal dialysis treatment with end-stage renal disease. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Children less than 13 years of age-Safety and efficacy have not been established. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Influenza A (treatment) or
Influenza B (treatment)-
Oral, 75 milligrams (mg) two times a day for 5 days. Oseltamivir should be initiated within 2 days of influenza symptoms.
Note: Renal Impairment: In patients with a creatinine clearance of less than 30 mL/min the recommended dose is 75 mg once daily for 5 days. Use of oseltamivir in patients with renal failure (creatinine clearance below 10 mL/min) has not been studied .
No recommended dose regimens are available for patients having routine hemodialysis and continuous peritoneal dialysis treatment with end-stage renal disease.
Influenza (prophylaxis) -
Oral, 75 mg once a day for at least 7 days. Oseltamivir should be initiated within 2 days of influenza exposure.
Note: Renal Impairment: In patients with a creatinine clearance between 10 and 30 mL/min, the recommended dose is 75 mg once every other day. No recommended dose regimens are available for patients having routine hemodialysis and continuous peritoneal dialysis treatment with end-stage renal disease. |
|
|
|
|
|